Halozyme SVP granted options and stock units

Halozyme Therapeutics reported that SVP and Chief Legal Officer Mark Howard Snyder received several equity awards on February 9, 2026.

Rhea-AI Filing Summary

Halozyme Therapeutics reported that SVP and Chief Legal Officer Mark Howard Snyder received several equity awards on February 9, 2026. He was granted an option to purchase 18,730 shares of common stock at an exercise price of $80.48, vesting one-fourth on the grant date and then monthly in equal installments.

He was also awarded 17,396 restricted stock units that vest in four equal annual installments starting one year after the grant, plus multiple performance stock unit awards. Performance stock units of 4,651, 7,808, and 29,502 shares became eligible to vest based on a performance period ending December 31, 2025 and remain subject to additional service-based vesting through the third anniversary of each original PSU grant date.

Insider Trade Summary

Grant/Award: 78,087 shares

Grant/Award 5 txns

Insider Snyder Mark Howard

Role SVP, CHIEF LEGAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	18,730	$0.00	$0.00
Grant/Award	Restricted Stock Units	17,396	$0.00	$0.00
Grant/Award	Performance Stock Units	4,651	$0.00	$0.00
Grant/Award	Performance Stock Units	7,808	$0.00	$0.00
Grant/Award	Performance Stock Units	29,502	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 18,730 contracts (Direct); Restricted Stock Units — 17,396 contracts (Direct); Performance Stock Units — 86,645 contracts (Direct)

Footnotes (5)

1. F1. This option vests one-fourth on such date and then 1/48th monthly thereafter.
2. F2. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
3. F3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
4. F4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
5. F5. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Halozyme (HALO) grant to SVP Mark Snyder?

Halozyme granted Mark Snyder an option for 18,730 shares at $80.48, 17,396 restricted stock units, and several performance stock unit awards totaling 4,651, 7,808, and 29,502 units, all tied to future service and performance-based vesting.

How do Mark Snyder’s new stock options at Halozyme (HALO) vest?

The option to purchase 18,730 Halozyme shares vests one-fourth on the grant date of February 9, 2026, then in 1/48th monthly installments thereafter. This structure provides gradual vesting over four years contingent on continued service with the company.

What is the vesting schedule for Halozyme (HALO) restricted stock units granted to Mark Snyder?

The 17,396 restricted stock units granted to Mark Snyder vest one-fourth on the first anniversary of the grant date, then one-fourth on each subsequent anniversary. This creates a four-year service-based vesting period designed to retain the executive over the long term.

How are Halozyme (HALO) performance stock units for Mark Snyder determined and vested?

Performance stock units were granted with a performance period ending December 31, 2025. Awards of 4,651, 7,808, and 29,502 units became eligible to vest based on that performance, but still require continued service through the third anniversary of each original grant date.

What does each Halozyme (HALO) restricted or performance stock unit represent?

Each restricted or performance stock unit represents a contingent right to receive one share of Halozyme common stock. Actual receipt depends on meeting specified vesting conditions, including performance results for the period ending December 31, 2025 and ongoing employment through future anniversary dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 09:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Snyder Mark Howard

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$80.48	02/09/2026		A		18,730		02/09/2027(1)	02/09/2036	Common Stock	18,730	$0	18,730	D
Restricted Stock Units	$0	02/09/2026		A		17,396		02/09/2027(2)	(2)	Common Stock	17,396	$0	17,396	D
Performance Stock Units	$0	02/09/2026		A		4,651		(3)	(3)	Common Stock	4,651	$0	12,016	D
Performance Stock Units	$0	02/09/2026		A		7,808		(4)	(4)	Common Stock	7,808	$0	45,127	D
Performance Stock Units	$0	02/09/2026		A		29,502		(5)	(5)	Common Stock	29,502	$0	29,502	D

Explanation of Responses:

1. This option vests one-fourth on such date and then 1/48th monthly thereafter.

2. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

5. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.